肿瘤坏死因子相关凋亡诱导配体TRAIL及其受体在急性髓系白血病细胞中的表达及意义

Expression and Its Significance of TRAIL and Its Receptors in Cells of Patients with Acute Myeloid Leukemia

为了检测肿瘤坏死因子相关凋亡诱导配体 (TRAIL)及其受体在急性髓系白血病细胞中的表达 ,并探讨其在白血病治疗中的意义 ,采用RT PCR方法及流式细胞术 ,对 39例急性髓系白血病细胞 (患者组 )、18例完全缓解白血病细胞 (缓解组 )和 2 1例正常人骨髓或外周血单个核细胞 (对照组 )表面TRAIL及其受体的表达进行检测。结果表明 :①患者组和缓解组TRAIL、DR4和DR5表达高 ,而DcR1和DcR2表达低。②缓解组DR5的表达高于患者组。③患者组和缓解组DR5的表达均高于DR4。④患者组AML不同亚型表达TRAIL及其受体相似。结论 :TRAIL及其受体在急性髓系白血病细胞中的表达具有明显的差异性。DR5在TRAIL介导的急性髓系白血病细胞凋亡中起重要的作用。

This study was aimed to detect the expression of TNF related apoptosis-inducing ligand(TRAIL) and its receptors on acute myeloid leukemic (AML) cells, and explore its possible role in leukemia therapy. RT-PCR and flow cytometry were used to detect the expression of TRAIL and its receptors on AML cells of 39 cases (patient group), AML cells of 18 cases with complete remission (CR group) and BMMNC or PBMNC of 21 normal persons (control group). The results showed that (1) TRAIL, DR4 and DR5 were highly expressed in both patient group and CR group, while the DcR1 and DcR2 were poorly expressed. (2) The level of DR5 expression in CR group was higher than that in patient group. (3) The level of DR5 was higher than DR4 in both patient group and CR group. (4) TRAIL and its receptors were expressed similarly in different subtypes of AML. In conclusion, there are differences between the expressions of TRAIL and its receptors in AML cells. DR5 may play an important role in TRAIL-inducing apoptosis of AML cells.